Literature DB >> 25600436

Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.

Matthew J Frigault1, Jihyun Lee1, Maria Ciocca Basil1, Carmine Carpenito1, Shinichiro Motohashi2, John Scholler1, Omkar U Kawalekar1, Sonia Guedan1, Shannon E McGettigan1, Avery D Posey1, Sonny Ang3, Laurence J N Cooper3, Jesse M Platt1, F Brad Johnson1, Chrystal M Paulos4, Yangbing Zhao1, Michael Kalos1, Michael C Milone1, Carl H June5.   

Abstract

This study compared second-generation chimeric antigen receptors (CAR) encoding signaling domains composed of CD28, ICOS, and 4-1BB (TNFRSF9). Here, we report that certain CARs endow T cells with the ability to undergo long-term autonomous proliferation. Transduction of primary human T cells with lentiviral vectors encoding some of the CARs resulted in sustained proliferation for up to 3 months following a single stimulation through the T-cell receptor (TCR). Sustained numeric expansion was independent of cognate antigen and did not require the addition of exogenous cytokines or feeder cells after a single stimulation of the TCR and CD28. Results from gene array and functional assays linked sustained cytokine secretion and expression of T-bet (TBX21), EOMES, and GATA-3 to the effect. Sustained expression of the endogenous IL2 locus has not been reported in primary T cells. Sustained proliferation was dependent on CAR structure and high expression, the latter of which was necessary but not sufficient. The mechanism involves constitutive signaling through NF-κB, AKT, ERK, and NFAT. The propagated CAR T cells retained a diverse TCR repertoire, and cellular transformation was not observed. The CARs with a constitutive growth phenotype displayed inferior antitumor effects and engraftment in vivo. Therefore, the design of CARs that have a nonconstitutive growth phenotype may be a strategy to improve efficacy and engraftment of CAR T cells. The identification of CARs that confer constitutive or nonconstitutive growth patterns may explain observations that CAR T cells have differential survival patterns in clinical trials. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25600436      PMCID: PMC4390458          DOI: 10.1158/2326-6066.CIR-14-0186

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  51 in total

1.  Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.

Authors:  Yangbing Zhao; Edmund Moon; Carmine Carpenito; Chrystal M Paulos; Xiaojun Liu; Andrea L Brennan; Anne Chew; Richard G Carroll; John Scholler; Bruce L Levine; Steven M Albelda; Carl H June
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

Review 2.  Genetic modification of T cells.

Authors:  Chiara Bonini; Malcolm K Brenner; Helen E Heslop; Richard A Morgan
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

Review 3.  Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.

Authors:  Bipulendu Jena; Gianpietro Dotti; Laurence J N Cooper
Journal:  Blood       Date:  2010-05-03       Impact factor: 22.113

4.  Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation.

Authors:  Nicole M Haynes; Joseph A Trapani; Michele W L Teng; Jacob T Jackson; Loretta Cerruti; Stephen M Jane; Michael H Kershaw; Mark J Smyth; Phillip K Darcy
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

5.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

6.  Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

Authors:  Michael C Milone; Jonathan D Fish; Carmine Carpenito; Richard G Carroll; Gwendolyn K Binder; David Teachey; Minu Samanta; Mehdi Lakhal; Brian Gloss; Gwenn Danet-Desnoyers; Dario Campana; James L Riley; Stephan A Grupp; Carl H June
Journal:  Mol Ther       Date:  2009-04-21       Impact factor: 11.454

7.  Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.

Authors:  Renier J Brentjens; Elmer Santos; Yan Nikhamin; Raymond Yeh; Maiko Matsushita; Krista La Perle; Alfonso Quintás-Cardama; Steven M Larson; Michel Sadelain
Journal:  Clin Cancer Res       Date:  2007-09-12       Impact factor: 12.531

8.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

Authors:  Carmine Carpenito; Michael C Milone; Raffit Hassan; Jacqueline C Simonet; Mehdi Lakhal; Megan M Suhoski; Angel Varela-Rohena; Kathleen M Haines; Daniel F Heitjan; Steven M Albelda; Richard G Carroll; James L Riley; Ira Pastan; Carl H June
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-11       Impact factor: 11.205

9.  Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer's disease.

Authors:  J Nicholas Lukens; Vivianna Van Deerlin; Christopher M Clark; Sharon X Xie; F Brad Johnson
Journal:  Alzheimers Dement       Date:  2009-11       Impact factor: 21.566

10.  Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.

Authors:  Harjeet Singh; Pallavi R Manuri; Simon Olivares; Navid Dara; Margaret J Dawson; Helen Huls; Perry B Hackett; Donald B Kohn; Elizabeth J Shpall; Richard E Champlin; Laurence J N Cooper
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

View more
  128 in total

Review 1.  Smart CARs engineered for cancer immunotherapy.

Authors:  Saul J Priceman; Stephen J Forman; Christine E Brown
Journal:  Curr Opin Oncol       Date:  2015-11       Impact factor: 3.645

2.  Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.

Authors:  Jenessa B Smith; Evripidis Lanitis; Denarda Dangaj; Elizabeth Buza; Mathilde Poussin; Caitlin Stashwick; Nathalie Scholler; Daniel J Powell
Journal:  Mol Ther       Date:  2016-07-21       Impact factor: 11.454

Review 3.  Delivery technologies for cancer immunotherapy.

Authors:  Rachel S Riley; Carl H June; Robert Langer; Michael J Mitchell
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

4.  A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.

Authors:  Sarah Nikiforow; Haesook T Kim; Heather Daley; Carol Reynolds; Kyle Thomas Jones; Philippe Armand; Vincent T Ho; Edwin P Alyea; Corey S Cutler; Jerome Ritz; Joseph H Antin; Robert J Soiffer; John Koreth
Journal:  Haematologica       Date:  2016-06-27       Impact factor: 9.941

Review 5.  Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse.

Authors:  Saad S Kenderian; David L Porter; Saar Gill
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-13       Impact factor: 5.742

6.  Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.

Authors:  Andrew R Haas; Janos L Tanyi; Mark H O'Hara; Whitney L Gladney; Simon F Lacey; Drew A Torigian; Michael C Soulen; Lifeng Tian; Maureen McGarvey; Anne Marie Nelson; Caitlin S Farabaugh; Edmund Moon; Bruce L Levine; J Joseph Melenhorst; Gabriela Plesa; Carl H June; Steven M Albelda; Gregory L Beatty
Journal:  Mol Ther       Date:  2019-07-30       Impact factor: 11.454

Review 7.  The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy.

Authors:  Felipe Bedoya; Matthew J Frigault; Marcela V Maus
Journal:  Mol Ther       Date:  2017-02-01       Impact factor: 11.454

8.  Blockade of BAFF Receptor BR3 on T Cells Enhances Their Activation and Cytotoxicity.

Authors:  Debra D Bloom; Sofiya Reshetylo; Cassandra Nytes; Claudia T Goodsett; Peiman Hematti
Journal:  J Immunother       Date:  2018-06       Impact factor: 4.456

9.  Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.

Authors:  Christopher A Klebanoff; Joseph G Crompton; Anthony J Leonardi; Tori N Yamamoto; Smita S Chandran; Robert L Eil; Madhusudhanan Sukumar; Suman K Vodnala; Jinhui Hu; Yun Ji; David Clever; Mary A Black; Devikala Gurusamy; Michael J Kruhlak; Ping Jin; David F Stroncek; Luca Gattinoni; Steven A Feldman; Nicholas P Restifo
Journal:  JCI Insight       Date:  2017-12-07

Review 10.  Driving CARs on the uneven road of antigen heterogeneity in solid tumors.

Authors:  Nan Chen; Xiaoyu Li; Navin K Chintala; Zachary E Tano; Prasad S Adusumilli
Journal:  Curr Opin Immunol       Date:  2018-03-16       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.